▟ Vinebot intrinsic value, daily

← back

VRTX Vertex Pharmaceuticals

pharma · valued with opus medium conviction · deep-dived 2026-10-29

BUY
Intrinsic value$391.53
Price (at call)$529.69
Margin of safety -26.1%
vs market (rating basis) +23.3%

CF cash machine funding a real pipeline; the price already assumes success in kidney and pain.

The story

Vertex holds a near-monopoly in cystic fibrosis. Its CFTR modulators (Trikafta, and now Alyftrek with its lower royalty burden) produce franchise-level margins and patent protection into the late 2030s. The company is putting that cash into diversification: Casgevy for sickle cell and beta-thalassemia, Journavx for non-opioid pain, and povetacicept and inaxaplin in kidney disease. It is a mature cash machine trying to buy a second growth act, and execution on that pipeline will decide its value beyond CF.

I kept every driver unchanged because nothing material has moved since September. TTM revenue of 12.59B and a 40% operating margin track the path toward 45% as Alyftrek's royalty savings arrive and the 2024 IPR&D charge fades from the comparison. Ten percent growth fits the 10.4% five-year CAGR. The 12-year horizon reflects CF exclusivity plus the pipeline runway, and a 0.9 beta suits defensive, diversified rare-disease revenue.

Value drivers

Revenue growth (Y1)10.0%
Terminal growth3.5%
Forecast horizon12y
Target operating margin45.0%
Years to target margin4
Sales-to-capital1.50
Beta0.90
Failure probability2.0%
Cost of capital (WACC)9.1%
Terminal WACC9.5%

Valuation bridge

PV of explicit FCFF46.99B
PV of terminal value49.19B
Equity value99.24B
÷ shares → per share$391.53

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 13.85B 10.0% 41.3% 4.87B 839.15M 4.03B 3.69B
2 15.15B 9.4% 42.5% 5.49B 868.52M 4.62B 3.88B
3 16.48B 8.8% 43.8% 6.14B 890.56M 5.25B 4.05B
4 17.84B 8.2% 45.0% 6.84B 904.15M 5.93B 4.19B
5 19.20B 7.6% 45.0% 7.36B 908.26M 6.45B 4.17B
6 20.56B 7.0% 45.0% 7.88B 901.97M 6.97B 4.14B
7 21.88B 6.5% 45.0% 8.38B 884.54M 7.50B 4.08B
8 23.17B 5.9% 45.0% 8.88B 855.42M 8.02B 4.00B
9 24.39B 5.3% 45.0% 9.34B 814.32M 8.53B 3.90B
10 25.53B 4.7% 45.0% 9.78B 761.19M 9.02B 3.78B
11 26.57B 4.1% 45.0% 10.18B 696.25M 9.48B 3.64B
12 27.50B 3.5% 45.0% 10.54B 620.05M 9.92B 3.49B

Key risks

  • Journavx and Casgevy ramps stay slow, so revenue remains concentrated in CF
  • Kidney readouts for povetacicept and inaxaplin disappoint, or competitors such as Otsuka's sibeprenlimab erode the IgAN opportunity
  • Drug pricing pressure from MFN and IRA policy, or a CF competitor, compresses the 45% margin

Catalysts

  • Povetacicept IgAN accelerated approval and launch trajectory
  • Journavx uptake data and Phase 3 results in diabetic peripheral neuropathy pain

History

DatePriceIntrinsicMoSRating
2026-10-29$529.69 $391.53 -26.1% BUY
2026-09-25$522.38 $384.70 -26.4% STRONG BUY
2026-08-24$548.05 $382.33 -30.2% BUY
2026-07-22$482.00 $345.66 -28.3% BUY
2026-07-21$480.50 $392.61 -18.3% N/A
2026-06-23$468.42 $317.62 -32.2% BUY